ERBB2 and inflammatory breast carcinoma: Within IBC, 24% are reported to be triple negative (11, 13) and 32% to 45% are HER2+ (11, 13–15) in contrast to 10% to 15% of triple-negative and 13% to 15% of HER2+ cases for the non-IBC population (16).